ArticleTherapeutics and clinical risk management2010
Growth hormone deficiency and cerebral palsy.
Article in Therapeutics and clinical risk management, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 37 citations in OpenAlex.
- Five-year outcomes after surgical treatment of infant postinfectious hydrocephalus in sub-Saharan Africa: results of a randomized trial.Journal of neurosurgery. Pediatrics · 2025Trial
- Growth hormone treatment in cerebral palsy: long-term impact on growth, outcomes, and complications.Pediatric research · 2026Article
- Cerebral Palsy Link to Sensorimotor System, Cognition, Emotion and Nociplastic Pain.Children (Basel, Switzerland) · 2025Review
- Case report: Epilepsy during the use of recombinant human growth hormone: a report on two cases and a literature review.Frontiers in pharmacology · 2024Article
- Management of Neonatal Isolated and Combined Growth Hormone Deficiency: Current Status.International journal of molecular sciences · 2023Review
- 5-year fracture risk among children with cerebral palsy.Pediatric research · 2023Article
- Associations of Circulating Insulin-Growth Factor-1 With Cognitive Functions and Quality of Life Domains in Ambulatory Young Adults With Cerebral Palsy: A Pilot Study.Frontiers in neurology · 2022Article
- Microsomic and macrosomic body structure in children and adolescents affected by syndromes or diseases associated with neurodysfunction.Scientific reports · 2021Article
- The relationship between lower limb muscle volume and body mass in ambulant individuals with bilateral cerebral palsy.BMC neurology · 2017Article
- Bone mineral density and insulin-like growth factor-1 in children with spastic cerebral palsy.Child's nervous system : ChNS : official journal of the International Society for Pediatric Neurosurgery · 2017Article
- Central Precocious Puberty and Response to GnRHa Therapy in Children with Cerebral Palsy and Moderate to Severe Motor Impairment: Data from a Longitudinal, Case-Control, Multicentre, Italian Study.International journal of endocrinology · 2017Article
- Learning and Memory Recoveries in a Young Girl Treated with Growth Hormone and Neurorehabilitation.Journal of clinical medicine · 2016Article
- Multiple Effects of Growth Hormone in the Body: Is it Really the Hormone for Growth?Clinical medicine insights. Endocrinology and diabetes · 2016Review
- High Postnatal Growth Hormone Levels Are Related to Cognitive Deficits in a Group of Children Born Very Preterm.The Journal of clinical endocrinology and metabolism · 2015Article
- Native and Complexed IGF-1: Biodistribution and Pharmacokinetics in Infantile Neuronal Ceroid Lipofuscinosis.Journal of drug delivery · 2012Article
- Effects of recombinant growth hormone (GH) replacement and psychomotor and cognitive stimulation in the neurodevelopment of GH-deficient (GHD) children with cerebral palsy: a pilot study.Therapeutics and clinical risk management · 2011Article
- Effects of recombinant growth hormone replacement and physical rehabilitation in recovery of gross motor function in children with cerebral palsy.Therapeutics and clinical risk management · 2010Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Cerebral palsy (CP) is a catastrophic acquired disease, occurring during development of the fetal or infant brain. It mainly affects the motor control centres of the developing brain, but can also affect cognitive functions, and is usually accompanied by a cohort of symptoms including lack of communication, epilepsy, and alterations in behavior. Most children with cerebral palsy exhibit a short stature, progressively declining from birth to puberty. We tested here whether this lack of normal growth might be due to an impaired or deficient growth hormone (GH) secretion. Our study sample comprised 46 CP children, of which 28 were male and 18 were female, aged between 3 and 11 years. Data obtained show that 70% of these children lack normal GH secretion. We conclude that GH replacement therapy should be implemented early for CP children, not only to allow them to achieve a normal height, but also because of the known neurotrophic effects of the hormone, perhaps allowing for the correction of some of the common disabilities experienced by CP children.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.